5th gen glp 1 agonist The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications Top GLP-1 Agonists Balance Weight

GLP-1 drugs may be prescribed for the following conditions as per American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) 2025 guidelines 11 : Primary glycaemic indication: GLP-1 RAs are recommended for adults with type 2 diabetes who have not reached their individualised A1C targets (typically when A1C is 1.5% above the agreed glycaemic goal) despite lifestyle measures and foundational therapy such as metformin

Therefore, the research and development of the relevant drugs and the replacement therapy of double GIP-GLP-1R agonists (e.g., tirzepatide) and triple GIP-GCG-GLP-1R (e.g., peptide 20) agonist are key research fields

Similar content being viewed by others Digital Features This article is published with digital features, including an infographic, to facilitate understanding of the article

Yet cardiomyocytes, the main muscle cells of the heart, and hepatocytes in the liver do not appear to express GLP-1 or GIP receptors in significant amounts

Starting with a low dose and titrating gradually can help minimise these effects